Sugi Predict

Sugi Predict / Compounds / SCHEMBL552610

SCHEMBL552610

SCHEMBL552610

O=C(O)CNC[C@@]1(n2ccc(=O)[nH]c2=O)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ SLC28A1 O00337 1/20 0.41
▸ SLC28A2 O43868 1/20 0.41
▸ SLC29A1 Q99808 1/20 0.41
▸ SLC28A3 Q9HAS3 1/20 0.41
▸ P2RY14 Q15391 3/20 0.36
▸ P2RY6 Q15077 4/20 0.32
▸ P2RY2 P41231 2/20 0.31
▸ P2RY4 P51582 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ PYGB P11216 1/20 0.31
▸ OGT O15294 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL382353 0.90 SLC28A1 (0.35) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL31533058 0.86 SLC28A1 (0.44) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL17371751 0.85 SLC28A1 (0.45) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL16148480 0.84 SLC28A1 (0.44) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL1532519 0.83 SLC28A1 (0.49) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL8941498 0.83 SLC28A1 (0.49) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL2301891 0.82 SLC28A1 (0.47) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL30889876 0.82 SLC28A1 (0.39) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL15019146 0.82 SLC28A1 (0.39) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL28250490 0.82 SLC28A1 (0.48) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026047603-A1 SARS-COV-2 IMMUNOGENIC COMPOSITIONS BioNTech SE (DE) 2026-03-05 — — WO disclosed
US-12435334-B2 Differential knockout of an allele of a heterozygous ELANE gene-II EMENDOBIO INC. (US) 2025-10-07 — — US disclosed
US-20250281593-A1 Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus UNIV PENNSYLVANIA (US) 2025-09-11 — — US disclosed
CN-119789852-A Compositions and methods for delivering RNA 再生技术有限责任公司 2025-04-08 — — CN disclosed
US-12157898-B2 Methods and compositions for modulating a genome FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2024-12-03 — — US disclosed
US-20240336945-A1 TREM COMPOSITIONS AND USES THEREOF ALLTRNA, INC. 2024-10-10 — — US disclosed
EP-4320236-A1 COMPOSITIONS AND METHODS FOR TREATING TDP-43 PROTEINOPATHY Maze Therapeutics, Inc. (US) 2024-02-14 — — EP disclosed
WO-2024031087-A2 INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION MODERNATX, INC. (US) 2024-02-08 — — WO disclosed
US-20240035049-A1 METHODS AND COMPOSITIONS FOR MODULATING A GENOME FLAGSHIP PIONEERING INNOVATIONS VI, LLC 2024-02-01 — — US disclosed
EP-4301405-A1 VLP ENTEROVIRAL VACCINES ModernaTX, Inc. (US) 2024-01-10 — — EP disclosed
US-8110559-B2 Hindered ester-based biodegradable linkers for oligonucleotide delivery ENZON PHARMACEUTICALS, INC. (US) 2012-02-07 — — US disclosed
US-20100233190-A1 TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS ENZON PHARMACEUTICALS, INC. (US) 2010-09-16 — — US disclosed
US-20100234444-A1 HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY ENZON PHARMACEUTICALS, INC. (US) 2010-09-16 — — US disclosed
EP-2215126-A2 COMPOSITIONS AND METHODS TO MODULATE CELL MEMBRANE RESEALING University Of Medicine And Dentistry Of New Jersey (US) 2010-08-11 — — EP disclosed
US-20090318538-A1 POLYMERIC OLIGONUCLEOTIDE PRODRUGS ENZON PHARMACEUTICALS, INC. (US) 2009-12-24 — — US disclosed
US-20090264635-A1 METHODS AND COMPOSITIONS FOR DEPLETING ABUNDANT RNA TRANSCRIPTS APPLERA CORPORATION (US) 2009-10-22 — — US disclosed
WO-2009073808-A2 COMPOSITIONS AND METHODS TO MODULATE CELL MEMBRANE RESEALING UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2009-06-11 — — WO disclosed
WO-2006113579-A2 TUMOR INHIBITION BY MODULATING SPROUTY EXPRESSION OR ACTIVITY MICHIGAN STATE UNIVERSITY (US) 2006-10-26 — — WO disclosed
US-20050118148-A1 Compositions and methods related to mammalian Maf-A VANDERBILT UNIVERSITY 2005-06-02 — — US disclosed
US-6846809-B2 PEI: DNA vector formulations for in vitro and in vivo gene delivery BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2005-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100233190-A1 TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS PAICS, FCGRT, DNPEP SLC28A1 1706/4885SLC28A2 1712/4885SLC29A1 206/4885
US-20250281593-A1 Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus RNMT, TLR3, NSUN3 SLC28A1 358/4885SLC28A2 430/4885SLC29A1 231/4885
US-20240336945-A1 TREM COMPOSITIONS AND USES THEREOF TRMT1, TARBP1, TRMT1L SLC28A1 1608/4885SLC28A2 1803/4885SLC29A1 623/4885
US-20090318538-A1 POLYMERIC OLIGONUCLEOTIDE PRODRUGS TYMP, PAICS, DPYD SLC28A1 362/4885SLC28A2 394/4885SLC29A1 54/4885
US-20100234444-A1 HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY VEGFA, DCLRE1B, MSN SLC28A1 2556/4885SLC28A2 3016/4885SLC29A1 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.